These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 25470105)

  • 1. Recognition of patients who would benefit from LAI antipsychotic treatment: how to assess adherence.
    Correll CU
    J Clin Psychiatry; 2014 Nov; 75(11):e29. PubMed ID: 25470105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
    Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
    Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia.
    Kane JM; McEvoy JP; Correll CU; Llorca PM
    CNS Drugs; 2021 Nov; 35(11):1189-1205. PubMed ID: 34636025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-acting injectable antipsychotics: recommendations for clinicians.
    Malla A; Tibbo P; Chue P; Levy E; Manchanda R; Teehan M; Williams R; Iyer S; Roy MA
    Can J Psychiatry; 2013 May; 58(5 Suppl 1):30S-5S. PubMed ID: 23945065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving treatment adherence in patients with schizophrenia.
    Kane JM
    J Clin Psychiatry; 2011 Sep; 72(9):e28. PubMed ID: 21951990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A qualitative study of experiences with and perceptions regarding long-acting injectable antipsychotics: Part I-patient perspectives.
    Iyer S; Banks N; Roy MA; Tibbo P; Williams R; Manchanda R; Chue P; Malla A
    Can J Psychiatry; 2013 May; 58(5 Suppl 1):14S-22S. PubMed ID: 23945063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing Treatment Choices to Improve Adherence and Outcomes in Schizophrenia.
    Kane JM; Correll CU
    J Clin Psychiatry; 2019 Sep; 80(5):. PubMed ID: 31536686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment adherence in schizophrenia and schizoaffective disorder.
    Goff DC; Hill M; Freudenreich O
    J Clin Psychiatry; 2011 Apr; 72(4):e13. PubMed ID: 21527119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rethinking the role of long-acting atypical antipsychotics in the community setting.
    Altamura AC; Aguglia E; Bassi M; Bogetto F; Cappellari L; De Giorgi S; Fagiolini A; Ferrannini L; Girardi P
    Int Clin Psychopharmacol; 2012 Nov; 27(6):336-49. PubMed ID: 22859065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient outcomes within schizophrenia treatment: a look at the role of long-acting injectable antipsychotics.
    Bera RB
    J Clin Psychiatry; 2014; 75 Suppl 2():30-3. PubMed ID: 24919169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Challenges in the design and conduct of controlled clinical effectiveness trials in schizophrenia.
    Rosenheck RA; Krystal JH; Lew R; Barnett PG; Thwin SS; Fiore L; Valley D; Huang GD; Neal C; Vertrees JE; Liang MH;
    Clin Trials; 2011 Apr; 8(2):196-204. PubMed ID: 21270143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maintenance treatment with long-acting injectable risperidone in first-episode schizophrenia: a randomized effectiveness study.
    Weiden PJ; Schooler NR; Weedon JC; Elmouchtari A; Sunakawa-McMillan A
    J Clin Psychiatry; 2012 Sep; 73(9):1224-33. PubMed ID: 22938760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Acting Injectable Antipsychotics: Where Do They Fit in the Treatment Plan?
    Correll CU; Lauriello J
    J Clin Psychiatry; 2018; 79(1):. PubMed ID: 29505193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Attitudinal barriers to prescribing LAI antipsychotics in the outpatient setting: communicating with patients, families, and caregivers.
    Kane JM
    J Clin Psychiatry; 2014 Dec; 75(12):e33. PubMed ID: 25551245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical guideline recommendations for antipsychotic long-acting injections.
    Kane JM; Garcia-Ribera C
    Br J Psychiatry Suppl; 2009 Nov; 52():S63-7. PubMed ID: 19880920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [French Society for Biological Psychiatry and Neuropsychopharmacology task force: Formal Consensus for the prescription of depot antipsychotics].
    Samalin L; Abbar M; Courtet P; Guillaume S; Lancrenon S; Llorca PM
    Encephale; 2013 Dec; 39 Suppl 4():189-203. PubMed ID: 24373464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using Long-Acting Injectable Antipsychotics to Enhance the Potential for Recovery in Schizophrenia.
    Correll CU; Lauriello J
    J Clin Psychiatry; 2020 Jun; 81(4):. PubMed ID: 32609958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of long-acting risperidone in psychiatric disorders: focus on efficacy, safety and cost-effectiveness.
    Keith S
    Expert Rev Neurother; 2009 Jan; 9(1):9-31. PubMed ID: 19102665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Explicit review of risperidone long-acting injection prescribing practice.
    Wheeler A; Vanderpyl J; Carswell C; Stojkovic M; Robinson E
    J Clin Pharm Ther; 2011 Dec; 36(6):651-63. PubMed ID: 22023342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psychiatrists' use, knowledge and attitudes to first- and second-generation antipsychotic long-acting injections: comparisons over 5 years.
    Patel MX; Haddad PM; Chaudhry IB; McLoughlin S; Husain N; David AS
    J Psychopharmacol; 2010 Oct; 24(10):1473-82. PubMed ID: 19477883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.